{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:33:42Z","timestamp":1788449622524,"version":"build-2803163510"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Immune checkpoint inhibitor pneumonitis (CIP) is a prevalent form of immunotherapy-induced pulmonary toxicity, ranking among the leading causes of mortality associated with immune checkpoint inhibitors (ICIs). Despite its significance, the risk stratification of CIP in advanced non-small cell lung cancer (NSCLC) remains uncertain. In this study, we conducted a comprehensive analysis, comparing various factors such as histological types, treatment regimens, PD-L1 expression levels, and EGFR\/ALK negativity in advanced NSCLC. Our investigation extends to evaluating the relative risk of developing CIP based on previous treatment history. This analysis aims to provide valuable insights for the identification of specific patient subgroups at higher risk, facilitating more effective risk management and precision therapy approaches.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>PubMed, Embase, and Cochrane databases were systematically searched up to February 16, 2023. We conducted a screening of randomized controlled trials (RCTs) that compared ICI monotherapy or its combination with chemotherapy in advanced NSCLC. The trials were categorized based on histological type, treatment regimen, PD-L1 expression level, EGFR\/ALK-negative status, and prior treatment history. Subsequently, the data were stratified into five subgroups, and the occurrences of all-grades (1\u20135) and high-grades (3\u20135) pneumonia events were extracted. Odds ratios (OR) and corresponding 95% confidence intervals (CI) were then calculated for further analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Twenty-two RCTs, encompassing 13,725 patients with advanced NSCLC, were included in this analysis. Regardless of histology (OR = 2.47, 95% CI 1.41\u20134.33, P = 0.002; OR = 1.84, 95% CI 1.10\u20133.09, P = 0.02), treatment regimen (OR = 3.27, 95% CI 2.00\u20135.35, P &lt; 0.00001; OR = 2.91, 95% CI 1.98\u20134.27, P &lt; 0.00001), PD-L1 expression level (OR = 5.11, 95% CI 2.58\u201310.12, P &lt; 0.00001; OR = 5.15, 95% CI 2.48\u201310.70, P &lt; 0.0001), negative EGFR\/ALK expression (OR = 4.32, 95% CI 2.22\u20138.41, P &lt; 0.0001; OR = 3.6, 95% CI 1.56\u20138.28, P = 0.003), whether there is a history of treatment (OR = 3.27, 95% CI 2.00\u20135.35, P &lt; 0.00001; OR = 2.74, 95% CI 1.75\u20134.29, P &lt; 0.0001), ICI use was associated with a higher risk of all-grade (1\u20135) and high-grade (3\u20135) pneumonia compared to chemotherapy. Subgroup analysis revealed that the squamous group, the ICI vs. combination chemotherapy (CT) group, the PD-L1 &gt; 50% group, and the previously untreated group had a higher risk of developing all-grade and grade 3\u20135 CIP (P &lt; 0.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In advanced NSCLC, ICI treatment was linked to an elevated risk of pneumonitis across all grades (1\u20135) as well as high-grade occurrences (3\u20135) compared to chemotherapy. Notably, individuals with squamous histology and high PD-L1 expression, along with those lacking a history of prior treatment, demonstrated a heightened susceptibility to developing immune-related pneumonitis of all grades (1\u20135) and high grades (3\u20135). These observations provide valuable insights for clinicians seeking to enhance the management of pulmonary toxicity associated with immunotherapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0301931","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T17:25:41Z","timestamp":1714411541000},"page":"e0301931","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials"],"prefix":"10.1371","volume":"19","author":[{"given":"Ying","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7327-0322","authenticated-orcid":true,"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"6","key":"pone.0301931.ref001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0301931.ref002","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"RL Siegel","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"pone.0301931.ref003","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for Stage IV Non\u2013Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"SB Hanna NH","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0301931.ref004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"J Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0301931.ref005","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis","volume":"2","author":"M Nishino","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"pone.0301931.ref006","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"P Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"issue":"11","key":"pone.0301931.ref007","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"F Barlesi","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"12","key":"pone.0301931.ref008","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors","volume":"4","author":"DY Wang","year":"2018","journal-title":"JAMA Oncology"},{"key":"pone.0301931.ref009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis","volume":"10","author":"Q Su","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0301931.ref010","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cam4.2104","article-title":"Risk of immune-related pneumonitis for PD1\/PD-L1 inhibitors: Systematic review and network meta-analysis","volume":"8","author":"Y Huang","year":"2019","journal-title":"Cancer Med"},{"key":"pone.0301931.ref011","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"issue":"17","key":"pone.0301931.ref012","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"H Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0301931.ref013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"J Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10030","key":"pone.0301931.ref014","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"L Fehrenbacher","year":"2016","journal-title":"The Lancet"},{"issue":"10027","key":"pone.0301931.ref015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"RS Herbst","year":"2016","journal-title":"The Lancet"},{"issue":"11","key":"pone.0301931.ref016","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"CJ Langer","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"19","key":"pone.0301931.ref017","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"M Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"pone.0301931.ref018","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non\u2013Small-Cell Lung Cancer","volume":"376","author":"DP Carbone","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"30","key":"pone.0301931.ref019","first-page":"34493457","article-title":"Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non\u2013Small-Cell Lung Cancer","volume":"35","author":"AS Ramaswamy Govindan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10066","key":"pone.0301931.ref020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"A Rittmeyer","year":"2017","journal-title":"The Lancet"},{"issue":"22","key":"pone.0301931.ref021","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"L Gandhi","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"pone.0301931.ref022","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"MD Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0301931.ref023","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer","volume":"379","author":"L Paz-Ares","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10183","key":"pone.0301931.ref024","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"TSK Mok","year":"2019","journal-title":"The Lancet"},{"issue":"7","key":"pone.0301931.ref025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"H West","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"5","key":"pone.0301931.ref026","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial","volume":"14","author":"Y-L Wu","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"pone.0301931.ref027","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2020.0409","article-title":"Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial","volume":"6","author":"O Arrieta","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"pone.0301931.ref028","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial","volume":"15","author":"R Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"pone.0301931.ref029","author":"S. Roy","year":"2020","journal-title":"Long-Term Outcomes and Retreatment Among Patients With Previously Treated, ProgrammedDeath-Ligand 1\u2013Positive, Advanced Non\u2013Small-Cell Lung Cancer in the KEYNOTE-010 Study"},{"issue":"4","key":"pone.0301931.ref030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial","volume":"16","author":"M Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10274","key":"pone.0301931.ref031","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"A Sezer","year":"2021","journal-title":"The Lancet"},{"issue":"3","key":"pone.0301931.ref032","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"C Zhou","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"issue":"8","key":"pone.0301931.ref033","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer","volume":"4","author":"Y Oshima","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"pone.0301931.ref034","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities","volume":"154","author":"K Suresh","year":"2018","journal-title":"Chest"},{"issue":"12","key":"pone.0301931.ref035","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors","volume":"13","author":"K Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"8","key":"pone.0301931.ref036","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study","volume":"15","author":"Y Suzuki","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"pone.0301931.ref037","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer","volume":"19","author":"DH Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"pone.0301931.ref038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","article-title":"Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody","volume":"69","author":"R Shibaki","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"pone.0301931.ref039","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"O Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"pone.0301931.ref040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"JY Cho","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"pone.0301931.ref041","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/0284186X.2019.1695062","article-title":"Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis","volume":"59","author":"K Ninomiya","year":"2020","journal-title":"Acta Oncol"},{"issue":"5","key":"pone.0301931.ref042","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41416-022-01832-4","article-title":"Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis","volume":"127","author":"Y Wang","year":"2022","journal-title":"Br J Cancer"},{"issue":"8","key":"pone.0301931.ref043","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41416-022-01929-w","article-title":"Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate","volume":"127","author":"A. Rizzo","year":"2022","journal-title":"Br J Cancer"},{"issue":"10","key":"pone.0301931.ref044","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"K Suresh","year":"2019","journal-title":"J Clin Invest"},{"issue":"7","key":"pone.0301931.ref045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"N Shaverdian","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"4","key":"pone.0301931.ref046","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer","volume":"20","author":"KR Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"pone.0301931.ref047","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials","volume":"152","author":"M Khunger","year":"2017","journal-title":"Chest"},{"issue":"6","key":"pone.0301931.ref048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061404","article-title":"Impact of Proton Pump Inhibitors. and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis","volume":"14","author":"A Rizzo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"pone.0301931.ref049","doi-asserted-by":"crossref","first-page":"103596","DOI":"10.1016\/j.critrevonc.2022.103596","article-title":"The impact of gender on The efficacy of immune. checkpoint inhibitors in cancer patients: The MOUSEION-01 study","volume":"170","author":"M Santoni","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"pone.0301931.ref050","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or. immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"M Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0301931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T17:26:13Z","timestamp":1714411573000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0301931"}},"subtitle":[],"editor":[{"given":"Sai-Ching Jim","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0301931","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}